Clinical Diagnosis of Hypertrophic Cardiomyopathy Over Time in the United States (A Population-Based Claims Analysis)

• Published in: The American journal of cardiology 2021-11, Vol.159, p.107-112
• Main Authors: Butzner, Michael, Maron, Martin, Sarocco, Phil, Rowin, Ethan, Teng, Chia-Chen, Tan, Hiangkiat, Stanek, Eric, Robertson, Laura
• Format: Article
• Language: English
• Subjects: Calendars; Cardiology; Cardiomyopathy; Cardiovascular diseases; Codes; Coronary artery disease; Diagnosis; Diagnostic tests; Disease; Enrollments; Health insurance; Heart diseases; Insurance claims; Magnetic resonance imaging; Medical diagnosis; Medicare; Mutation; Patients; Pharmacy; Point mutation; Population; Signs and symptoms
• ISSN: 0002-9149; 1879-1913
• DOI: 10.1016/j.amjcard.2021.08.024

Hypertrophic cardiomyopathy (HC) is a common genetic heart disease. However, the number of gene mutation carriers who develop HC and manifest clinical symptoms is not well established. Our objective was to estimate annual prevalence and incidence rates of clinically diagnosed HC in the United States. Data from the HealthCore Integrated Research Database (HIRD) were interrogated for years 2013–2019 to identify patients with ≥1 claim of HC International Classification of Diseases, Clinical Modification Ninth and Tenth Revision diagnosis codes. In 2013, among 16,243,109 patients, 8,526 were identified with HC, yielding an estimated prevalence of clinically diagnosed HC of 0.052% (0.035% for obstructive [oHC], 0.017% for nonobstructive [nHC]). This prevalence yielded an estimated 164,403 patients with clinical diagnosis of HC. For the same year, the incidence of new HC diagnoses was 0.030% (0.020% for oHC, 0.010% for nHC). Over the following 6 years, prevalence and incidence of HC increased by 0.005%/year (p